{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:00:17Z","timestamp":1785466817400,"version":"3.56.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.oftale.2026.502562","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T16:41:32Z","timestamp":1776444092000},"page":"502562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Associations of dose adjustment with efficacy and safety of faricimab for age-related macular degeneration disorders: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1485-9193","authenticated-orcid":false,"given":"B.","family":"Benedictus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9073-5839","authenticated-orcid":false,"given":"S.T.","family":"Alaydrus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3259-1450","authenticated-orcid":false,"given":"H.K.","family":"Ronik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7638-9490","authenticated-orcid":false,"given":"Y.A.","family":"Dwinastiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0151-0124","authenticated-orcid":false,"given":"B.","family":"Priscilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Nova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oftale.2026.502562_bib0005","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.future.2018.05.001","article-title":"Age-related Macular Degeneration detection using deep convolutional neural network","volume":"87","author":"Tan","year":"2018","journal-title":"Future Gener Comput Syst"},{"issue":"9","key":"10.1016\/j.oftale.2026.502562_bib0010","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/bph.15459","article-title":"Emerging therapies and their delivery for treating age\u2010related macular degeneration","volume":"179","author":"Thomas","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"12","key":"10.1016\/j.oftale.2026.502562_bib0015","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/S0161-6420(96)30389-8","article-title":"Deep retinal vascular anomalous complexes in advanced age-related macular degeneration","volume":"103","author":"Hartnett","year":"1996","journal-title":"Ophthalmology"},{"issue":"15","key":"10.1016\/j.oftale.2026.502562_bib0020","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1001\/jama.291.15.1900","article-title":"Age-related macular degeneration is the leading cause of blindness","volume":"291","author":"Bressler","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.oftale.2026.502562_bib0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/17469899.3.1.43","article-title":"Trend of retinal diseases in developing countries","volume":"3","author":"Nazimul","year":"2008","journal-title":"Exp Rev Ophthalmol"},{"issue":"14","key":"10.1016\/j.oftale.2026.502562_bib0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1167\/iovs.62.14.26","article-title":"Retinal and choroidal vascular diseases: past, present, and future: the 2021 proctor lecture","volume":"62","author":"Campochiaro","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.oftale.2026.502562_bib0035","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.oftale.2026.502562_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1138428","article-title":"Trends and disparities in disease burden of age-related macular degeneration from 1990 to 2019: results from the global burden of disease study 2019","volume":"11","author":"Jiang","year":"2023","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.oftale.2026.502562_bib0045","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.gendis.2021.02.009","article-title":"Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy","volume":"9","author":"Deng","year":"2022","journal-title":"Genes Dis"},{"issue":"8","key":"10.1016\/j.oftale.2026.502562_bib0050","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/bjophthalmol-2019-314422","article-title":"Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis","volume":"104","author":"Li","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.oftale.2026.502562_bib0055","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/archophthalmol.2011.376","article-title":"Prevalence of and risk factors for age-related macular degeneration in a multiethnic Asian cohort","volume":"130","author":"Tai","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oftale.2026.502562_bib0060","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.890732","article-title":"The efficacy and safety of brolucizumab for the treatment of nAMD: a systematic review and meta-analysis","volume":"13","author":"Chuan","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.oftale.2026.502562_bib0065","article-title":"Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment","volume":"26","author":"Vyawahare","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.oftale.2026.502562_bib0070","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.oftale.2026.502562_bib0075","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"10326","key":"10.1016\/j.oftale.2026.502562_bib0080","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.oftale.2026.502562_bib0085","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1007\/s00417-023-06071-8","article-title":"Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-year subgroup analysis of the TENAYA and LUCERNE trials","volume":"261","author":"Takahashi","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.oftale.2026.502562_bib0090","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10384-023-00985-w","article-title":"Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial","volume":"67","author":"Mori","year":"2023","journal-title":"Jpn J Ophthalmol"},{"issue":"9","key":"10.1016\/j.oftale.2026.502562_bib0095","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","article-title":"Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial","volume":"138","author":"Sahni","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"10.1016\/j.oftale.2026.502562_bib0100","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","article-title":"Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial","volume":"138","author":"Khanani","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.oftale.2026.502562_bib0105","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s10384-023-00979-8","article-title":"Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial","volume":"67","author":"Shimura","year":"2023","journal-title":"Jpn J Ophthalmol"},{"issue":"8","key":"10.1016\/j.oftale.2026.502562_bib0110","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oftale.2026.502562_bib0115","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/APO.0000000000000634","article-title":"Efficacy, durability, and safety of faricimab in patients from Asian countries with diabetic macular edema: 1-year subgroup analysis of the phase III YOSEMITE and RHINE trials","volume":"12","author":"Ishida","year":"2023","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"11","key":"10.1016\/j.oftale.2026.502562_bib0120","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1007\/s00417-024-06531-9","article-title":"Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes","volume":"262","author":"Agostini","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.oftale.2026.502562_bib0125","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00417-024-06695-4","article-title":"Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases","volume":"263","author":"Chaudhary","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"10.1016\/j.oftale.2026.502562_bib0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1167\/tvst.13.11.13","article-title":"Ocular pharmacodynamics of intravitreal faricimab in patients with neovascular age-related macular degeneration or diabetic macular edema","volume":"13","author":"Diack","year":"2024","journal-title":"Trans Vis Sci Tech"},{"issue":"1","key":"10.1016\/j.oftale.2026.502562_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100111","article-title":"YOSEMITE and RHINE","volume":"2","author":"Eter","year":"2022","journal-title":"Ophthalmol Sci"},{"issue":"7","key":"10.1016\/j.oftale.2026.502562_bib0140","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1358\/dof.2020.45.7.3127028","article-title":"Faricimab. Anti-Ang-2\/anti-VEGF-A bispecific antibody, treatment of diabetic macular edema, treatment of wet age-related macular degeneration","volume":"45","author":"Hussain","year":"2020","journal-title":"Drugs Future"},{"issue":"5","key":"10.1016\/j.oftale.2026.502562_bib0145","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.molmed.2022.03.004","article-title":"Viewpoints: dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye","volume":"28","author":"Koh","year":"2022","journal-title":"Trends Mol Med"},{"issue":"6","key":"10.1016\/j.oftale.2026.502562_bib0150","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.survophthal.2024.07.006","article-title":"Role of inflammation in diabetic macular edema and neovascular age-related macular degeneration","volume":"69","author":"Vujosevic","year":"2024","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"10.1016\/j.oftale.2026.502562_bib0155","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.oftale.2026.502562_bib0160","doi-asserted-by":"crossref","first-page":"100","DOI":"10.17116\/oftalma2024140061100","article-title":"Dual inhibition of VEGF-A and angiopoietin-2 in the treatment of neovascular age-related macular degeneration and diabetic macular edema","volume":"140","author":"Zolotarev","year":"2024","journal-title":"Rus Ann Ophthal"},{"issue":"5","key":"10.1016\/j.oftale.2026.502562_bib0165","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s40123-023-00779-w","article-title":"Visual and anatomical outcomes after initial intravitreal faricimab injection for neovascular age-related macular degeneration in patients with prior treatment history","volume":"12","author":"Inoda","year":"2023","journal-title":"Ophthalmol Ther"},{"issue":"11","key":"10.1016\/j.oftale.2026.502562_bib0170","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1167\/tvst.13.11.14","article-title":"Ocular pharmacokinetics of faricimab following intravitreal administration in patients with retinal disease","volume":"13","author":"Diack","year":"2024","journal-title":"Trans Vis Sci Tech"},{"issue":"5","key":"10.1016\/j.oftale.2026.502562_bib0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178230","article-title":"Association between aqueous humor and vitreous fluid levels of Th17 cell-related cytokines in patients with proliferative diabetic retinopathy","volume":"12","author":"Takeuchi","year":"2017","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.oftale.2026.502562_bib0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12950-019-0214-2","article-title":"Anti-vascular endothelial growth factor agent reduces inflammation in macular edema with central retinal vein occlusion","volume":"16","author":"Mashima","year":"2019","journal-title":"J Inflamm"},{"issue":"4","key":"10.1016\/j.oftale.2026.502562_bib0185","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3892\/etm.2021.9763","article-title":"Effect of intravitreal conbercept injection on VEGF\u2011A and \u2011B levels in the aqueous and vitreous humor of patients with proliferative diabetic retinopathy","volume":"21","author":"Zhang","year":"2021","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.oftale.2026.502562_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/292615","article-title":"ET-1 plasma levels, aqueous flare, and choroidal thickness in patients with retinitis pigmentosa","volume":"2015","author":"Strobbe","year":"2015","journal-title":"J Ophthalmol"},{"issue":"2","key":"10.1016\/j.oftale.2026.502562_bib0195","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1167\/iovs.62.2.24","article-title":"Retinal Aquaporin-4 and regulation of water inflow into the vitreous body","volume":"62","author":"Ueki","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.oftale.2026.502562_bib0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125329","article-title":"Study of 27 aqueous humor cytokines in type 2 diabetic patients with or without macular edema","volume":"10","author":"Dong","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.oftale.2026.502562_bib0205","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s10384-012-0144-5","article-title":"Infectious causes of posterior uveitis and panuveitis in Thailand","volume":"56","author":"Kongyai","year":"2012","journal-title":"Jpn J Ophthalmol"},{"issue":"23","key":"10.1016\/j.oftale.2026.502562_bib0210","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.3390\/jcm12237401","article-title":"Subclinical ocular changes after intravitreal injections of different anti-VEGF agents for neovascular age-related macular degeneration","volume":"12","author":"Matsubara","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.oftale.2026.502562_bib0215","first-page":"1","article-title":"Tissue distribution of trans-resveratrol and its metabolites after oral administration in human eyes","volume":"2017","author":"Wang","year":"2017","journal-title":"J Ophthalmol"},{"issue":"12","key":"10.1016\/j.oftale.2026.502562_bib0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277313","article-title":"Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: an interventional study","volume":"17","author":"Orii","year":"2022","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.oftale.2026.502562_bib0225","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1167\/iovs.16-19686","article-title":"Association between aqueous flare and epiretinal membrane in retinitis pigmentosa","volume":"57","author":"Fujiwara","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oftale.2026.502562_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/3727543","article-title":"Anterior chamber flare as an objective and quantitative noninvasive method for oculopathy in transthyretin V30M amyloidosis patients","volume":"2018","author":"Beir\u00e3o","year":"2018","journal-title":"J Ophthalmol"},{"issue":"1","key":"10.1016\/j.oftale.2026.502562_bib0235","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1038\/s41598-022-09377-5","article-title":"Increased angiogenic factors in the aqueous and vitreous humors after disinsertion of extraocular muscle and the effects of triamcinolone acetate injection","volume":"12","author":"Suk-Gyu","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.oftale.2026.502562_bib0240","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-45616-z","article-title":"Measurement of vitreous humor pressure in vivo using an optic fiber pressure sensor","volume":"13","author":"Mimura","year":"2023","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.oftale.2026.502562_bib0245","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/jop.2011.0026","article-title":"Intraocular penetration of micafungin in patient with Candida albicans endophthalmitis","volume":"27","author":"Mochizuki","year":"2011","journal-title":"J Ocular Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.oftale.2026.502562_bib0250","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10792-024-03226-2","article-title":"Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema","volume":"44","author":"Pichi","year":"2024","journal-title":"Int Ophthalmol"},{"issue":"1","key":"10.1016\/j.oftale.2026.502562_bib0255","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000360186","article-title":"Detection of antiranibizumab antibodies among patients with exudative age-related macular degeneration","volume":"232","author":"Leveziel","year":"2014","journal-title":"Ophthalmologica"},{"issue":"1","key":"10.1016\/j.oftale.2026.502562_bib0260","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/IAE.0000000000001923","article-title":"EXIT strategy in a treat-and-extend regimen for exudative age-related macular degeneration","volume":"39","author":"Arendt","year":"2019","journal-title":"Retina"},{"issue":"11","key":"10.1016\/j.oftale.2026.502562_bib0265","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamaophthalmol.2024.3828","article-title":"Sterile intraocular inflammation associated with faricimab","volume":"142","author":"Cozzi","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oftale.2026.502562_bib0270","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2147\/OPTH.S409822","article-title":"Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration","volume":"17","author":"Leung","year":"2023","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"10.1016\/j.oftale.2026.502562_bib0275","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s00417-024-06377-1","article-title":"Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial","volume":"262","author":"Koizumi","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.oftale.2026.502562_bib0280","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1038\/s41598-021-83811-y","article-title":"Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema","volume":"11","author":"Hirano","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.oftale.2026.502562_bib0285","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2024-001967","article-title":"Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations","volume":"10","author":"Wong","year":"2025","journal-title":"BMJ Open Ophth"},{"key":"10.1016\/j.oftale.2026.502562_bib0290","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1192464","article-title":"Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia\/reperfusion","volume":"17","author":"Canonica","year":"2023","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.oftale.2026.502562_bib0295","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/PPA.S291983","article-title":"Adherence to treatment in patients with rheumatoid arthritis from Spain","volume":"15","author":"Pombo-Suarez","year":"2021","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.oftale.2026.502562_bib0300","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/11206721211001313","article-title":"Two-year results of a treat and extend regimen with aflibercept in Caucasian patients with aneurysmal type 1 neovascularization","volume":"32","author":"Montero Hern\u00e1ndez","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.oftale.2026.502562_bib0305","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/8583348","article-title":"Durability and efficacy of faricimab in treatment-resistant retinal edema utilizing \u201creal-world\u201d dosing regimens","volume":"2024","author":"Savant","year":"2024","journal-title":"J Ophthalmol"},{"issue":"1","key":"10.1016\/j.oftale.2026.502562_bib0310","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/8583348","article-title":"Durability and Efficacy of faricimab in treatment\u2010resistant retinal edema utilizing \u201creal\u2010world\u201d dosing regimens","volume":"2024","author":"Savant","year":"2024","journal-title":"J Ophthalmol"},{"issue":"1","key":"10.1016\/j.oftale.2026.502562_bib0315","doi-asserted-by":"crossref","first-page":"9087","DOI":"10.1038\/s41598-024-59894-8","article-title":"One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment","volume":"14","author":"Takahashi","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.oftale.2026.502562_bib0320","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2147\/OPTH.S463624","article-title":"Real-world outcomes of faricimab treatment for neovascular age-related macular degeneration and diabetic macular edema","volume":"18","author":"Quah","year":"2024","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.oftale.2026.502562_bib0325","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1159\/000540194","article-title":"Efficacy and durability of faricimab in na\u00efve eyes with neovascular age-related macular degeneration","volume":"67","author":"Toto","year":"2024","journal-title":"Ophthalmic Res"}],"container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173579426001040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173579426001040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:31:11Z","timestamp":1785465071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173579426001040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2173579426001040"],"URL":"https:\/\/doi.org\/10.1016\/j.oftale.2026.502562","relation":{},"ISSN":["2173-5794"],"issn-type":[{"value":"2173-5794","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations of dose adjustment with efficacy and safety of faricimab for age-related macular degeneration disorders: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oftale.2026.502562","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.oftal.2026.502562","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Oftalmolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"502562"}}